X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (386) 386
index medicus (274) 274
female (241) 241
hand-foot syndrome - etiology (211) 211
male (204) 204
middle aged (161) 161
aged (136) 136
oncology (131) 131
adult (130) 130
antineoplastic agents - adverse effects (119) 119
chemotherapy (87) 87
hand-foot syndrome (86) 86
cancer (84) 84
sorafenib (81) 81
capecitabine (71) 71
treatment outcome (69) 69
antineoplastic agents - therapeutic use (62) 62
aged, 80 and over (58) 58
dermatology (58) 58
niacinamide - analogs & derivatives (58) 58
therapy (58) 58
care and treatment (55) 55
child, preschool (55) 55
disease-free survival (54) 54
infant (50) 50
sunitinib (50) 50
breast neoplasms - drug therapy (47) 47
risk factors (45) 45
children (44) 44
drug eruptions - etiology (44) 44
fluorouracil - adverse effects (44) 44
antineoplastic combined chemotherapy protocols - adverse effects (43) 43
child (43) 43
deoxycytidine - analogs & derivatives (43) 43
protein kinase inhibitors - adverse effects (43) 43
palmar-plantar erythrodysesthesia (41) 41
fluorouracil - analogs & derivatives (40) 40
medicine & public health (40) 40
trial (40) 40
retrospective studies (39) 39
infectious diseases (38) 38
analysis (37) 37
antimetabolites, antineoplastic - adverse effects (37) 37
antineoplastic agents (37) 37
antineoplastic combined chemotherapy protocols - therapeutic use (37) 37
carcinoma, renal cell - drug therapy (37) 37
hand (37) 37
kidney neoplasms - drug therapy (37) 37
pharmacology & pharmacy (37) 37
antimitotic agents (36) 36
deoxycytidine - adverse effects (36) 36
hand-foot skin reaction (36) 36
epidemiology (35) 35
hand, foot and mouth disease - virology (35) 35
research (35) 35
coxsackievirus infections (34) 34
hand, foot and mouth disease - epidemiology (34) 34
indoles - adverse effects (34) 34
phenylurea compounds - adverse effects (34) 34
skin (34) 34
young adult (34) 34
drug administration schedule (33) 33
toxicity (33) 33
outbreak (32) 32
efficacy (31) 31
niacinamide - adverse effects (31) 31
breast neoplasms - pathology (30) 30
diarrhea - chemically induced (30) 30
liver neoplasms - drug therapy (30) 30
pyridines - adverse effects (30) 30
pyrroles - adverse effects (30) 30
pediatrics (29) 29
antineoplastic agents - administration & dosage (28) 28
health aspects (28) 28
neoplasms - drug therapy (28) 28
breast cancer (27) 27
prognosis (27) 27
fluorouracil - administration & dosage (26) 26
medical research (26) 26
prospective studies (26) 26
protein kinase inhibitors - therapeutic use (26) 26
doxorubicin - adverse effects (25) 25
fatigue - chemically induced (25) 25
hand-foot syndrome - pathology (25) 25
pegylated liposomal doxorubicin (25) 25
renal-cell carcinoma (25) 25
adolescent (24) 24
carcinoma, hepatocellular - drug therapy (24) 24
complications and side effects (24) 24
hand-foot-and-mouth disease (24) 24
medicine (24) 24
metastasis (24) 24
phenylurea compounds (24) 24
phenylurea compounds - therapeutic use (24) 24
quality of life (24) 24
deoxycytidine - administration & dosage (23) 23
hematology, oncology and palliative medicine (23) 23
incidence (23) 23
china (22) 22
double-blind (22) 22
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (390) 390
French (11) 11
Japanese (7) 7
German (5) 5
Chinese (3) 3
Dutch (1) 1
Hungarian (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2015, Volume 33, Issue 2, pp. 172 - 179
Purpose This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma... 
ANGIOGENESIS | ONCOLOGY | PATHWAY | SUNITINIB | ABT-869 | RISK | BRIVANIB | INHIBITOR | CANCER | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Hand-Foot Syndrome - etiology | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - etiology | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Hypertension - chemically induced | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Liver Neoplasms - pathology | Carcinoma, Hepatocellular - etiology | Odds Ratio | Drug Administration Schedule | Risk Factors | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Niacinamide - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Sorafenib | Carcinoma, Hepatocellular - pathology | Aged | Indazoles - adverse effects | Indazoles - therapeutic use | Bone3 | ORIGINAL REPORTS | Bios3
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2012, Volume 57, Issue 4, pp. 821 - 829
Background & Aims The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall... 
Gastroenterology and Hepatology | Subset analyses | Time to progression | Hepatocellular carcinoma | Disease control rate | Overall survival | Sorafenib | SURVIVAL | DESIGN | MANAGEMENT | PROGNOSIS | RISK | NATURAL-HISTORY | CIRRHOSIS | STAGING SYSTEMS | CLINICAL-TRIALS | GASTROENTEROLOGY & HEPATOLOGY | EPIDEMIOLOGY | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Liver Neoplasms - therapy | Hand-Foot Syndrome - etiology | Hepatitis C, Chronic - complications | Diarrhea - chemically induced | Liver Neoplasms - etiology | Carcinoma, Hepatocellular - drug therapy | Time Factors | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Female | Liver Neoplasms - pathology | Carcinoma, Hepatocellular - etiology | Alcoholism - complications | Severity of Illness Index | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Proportional Hazards Models | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Tumor Burden | Disease Progression | Hepatitis B, Chronic - complications | Carcinoma, Hepatocellular - pathology | Aged | Carcinoma, Hepatocellular - therapy | Neoplasm Staging | Antimitotic agents | Medical colleges | Liver cancer | Care and treatment | Analysis | Clinical trials | Product development | Hepatoma | Antineoplastic agents
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 13, pp. 1448 - 1454
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2147 - 2159
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2012, Volume 67, Issue 5, pp. 1025 - 1039
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9977, pp. 1509 - 1510
Journal Article
Cancer, ISSN 0008-543X, 09/2017, Volume 123, Issue 18, pp. 3602 - 3608
BACKGROUND Palmar‐plantar erythrodysesthesia syndrome (PPES) is an uncommon side effect of high‐dose cytarabine or methotrexate. Prior case reports of PPES... 
cytarabine | methotrexate | susceptibility | pediatric oncology | chemotherapy | palmar‐plantar erythrodysesthesia syndrome | palmar-plantar erythrodysesthesia syndrome | ACRAL ERYTHEMA | CHILDHOOD | TUMORS | CHILDREN | HAND-FOOT-SYNDROME | THERAPY | PHARMACOKINETICS | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | ASSOCIATION | Hand-Foot Syndrome - epidemiology | Multivariate Analysis | Age Distribution | Follow-Up Studies | Humans | Child, Preschool | Male | Hematologic Neoplasms - pathology | Cytarabine - adverse effects | Hand-Foot Syndrome - etiology | Incidence | Dose-Response Relationship, Drug | Female | Retrospective Studies | Odds Ratio | Child | Databases, Factual | Severity of Illness Index | Drug Administration Schedule | Risk Assessment | Hand-Foot Syndrome - physiopathology | Cytarabine - administration & dosage | Methotrexate - adverse effects | Analysis of Variance | Adolescent | Hematologic Neoplasms - drug therapy | Sex Distribution | Methotrexate - administration & dosage | Infusions, Intravenous | Complications and side effects | Care and treatment | Cytarabine | Palmar-plantar erythrodysesthesia | Dosage and administration | Children | Methotrexate | Risk factors | Dexamethasone | Narcotics | Identification methods | Health risks | Case reports | Genomes | Multivariate analysis | Risk analysis | Gene expression | Patients | Quantitative trait loci | Pain | Opioids | Skin | Health risk assessment | Age | Cancer | Geriatrics
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2015, Volume 33, Issue 22, pp. 2444 - 2449
Journal Article
British Journal of Cancer, ISSN 0007-0920, 01/2016, Volume 114, Issue 2, pp. 163 - 170
Journal Article